Evidence map›Paper›PMID 27041575›Full record

ArticleOncogene2016

An ultra-deep sequencing strategy to detect sub-clonal TP53 mutations in presentation chronic lymphocytic leukaemia cases using multiple polymerases.

L Worrillow, P Baskaran, M A Care, A Varghese, T Munir, P A Evans, S J O'Connor, A Rawstron, L Hazelwood, R M Tooze and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

L WorrillowSection of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
P BaskaranDepartment of Evolutionary Biology, Max Planck Institute for Developmental Biology, Tuebingen, Germany.
M A CareSection of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
A VargheseHaematological Malignancy Diagnostic Services, Leeds Teaching Hospitals National Health Services Trust, Leeds, UK.
T MunirHaematological Malignancy Diagnostic Services, Leeds Teaching Hospitals National Health Services Trust, Leeds, UK.
P A EvansHaematological Malignancy Diagnostic Services, Leeds Teaching Hospitals National Health Services Trust, Leeds, UK.
S J O'ConnorHaematological Malignancy Diagnostic Services, Leeds Teaching Hospitals National Health Services Trust, Leeds, UK.
A RawstronHaematological Malignancy Diagnostic Services, Leeds Teaching Hospitals National Health Services Trust, Leeds, UK.
L HazelwoodCancer Research UK, Ling Ka Shing Centre, University of Cambridge, Cambridge, UK.
R M ToozeSection of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
P HillmenSection of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
D J NewtonSection of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukaemia (CLL) is the most common clonal B-cell disorder characterized by clonal diversity, a relapsing and remitting course, and in its aggressive forms remains largely incurable. Current front-line regimes include agents such as fludarabine, which act primarily via the DNA damage response pathway. Key to this is the transcription factor p53. Mutations in the TP53 gene, altering p53 functionality, are associated with genetic instability, and are present in aggressive CLL. Furthermore, the emergence of clonal TP53 mutations in relapsed CLL, refractory to DNA-damaging therapy, suggests that accurate detection of sub-clonal TP53 mutations prior to and during treatment may be indicative of early relapse. In this study, we describe a novel deep sequencing workflow using multiple polymerases to generate sequencing libraries (MuPol-Seq), facilitating accurate detection of TP53 mutations at a frequency as low as 0.3%, in presentation CLL cases tested. As these mutations were mostly clustered within the regions of TP53 encoding DNA-binding domains, essential for DNA contact and structural architecture, they are likely to be of prognostic relevance in disease progression. The workflow described here has the potential to be implemented routinely to identify rare mutations across a range of diseases.

Indexed as

AdultAgedFemaleHigh-Throughput Nucleotide SequencingHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedMutationNeoplasm Recurrence, LocalPrognosisTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID27041575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.